Comparison of the effectiveness of three different desensitizing toothpastes in reducing dentin hypersensitivity: A 4-week clinical study.

AIM: To compare the effectiveness of three different desensitizing toothpastes containing potassium salt, natural ingredients, and 8% arginine in reducing dentin hypersensitivity (DH). MATERIALS AND METHODS: A 4-week study was conducted on 45 adult patients suffering from hypersensitivity associated with cervical abrasion of two or more teeth anterior to the molars. Patients were divided into three toothpaste groups as follows: Group I: potassium salt, Group II: herbal desensitizing paste containing natural ingredients, and Group III: 8% arginine. Using tactile stimulus and air stimulus, the sensitivity scores were recorded using Visual Analog Scale (VAS) at baseline, immediately after application, after 1 week, after 2 weeks, and after 4 weeks. STATISTICAL ANALYSIS: One-way ANOVA test and post hoc Tukey's test were used, and P ≤ 0.05 was considered statistically significant. RESULTS: Group III showed significantly better reduction in DH at all time intervals when compared with Group I. Group III was significantly better than Group II at 1, 2, and 4 weeks. CONCLUSION: Desensitizing toothpaste containing 8% arginine was found to be the most effective in the reduction of DH after a single application up to a period of 4 weeks followed by herbal desensitizing toothpaste and potassium salt-containing toothpaste.

The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer.

INTRODUCTION: For more than 50 years, small cell lung cancer (SCLC) has been staged mainly as either limited or extensive stage disease. Small published series of resected SCLC have suggested that the tumor, node, metastases (TNM) pathologic staging correlates with the survival of resected patients. Recent analysis of the 8088 cases of SCLC in the International Association for the Study of Lung Cancer (IASLC) database demonstrated the usefulness of clinical TNM staging in this malignancy. The IASLC data bank contains an unprecedented number of resected SCLC cases with pathologic staging information. This analysis was undertaken to examine the impact of the TNM system on the pathologic staging of SCLC and to assess the new IASLC proposals in this subtype of lung cancer. METHODS: Using the IASLC database, survival analyses were performed for resected patients with SCLC. Prognostic groups were compared, and the new IASLC TNM proposals were applied to this population and to the Surveillance, Epidemiology, and End Results (SEER) database. RESULTS: The IASLC database contained 349 cases of resected SCLC where pathologic TNM staging was available. Survival after resection correlated with both T and N category with nodal status having a stronger influence on survival. Stage groupings using the 6th edition of TNM clearly identify patient subgroups with different prognoses. The IASLC proposals for the 7th edition of TNM classification also apply to this population and to the SEER database. CONCLUSION: This analysis further strengthens our previous recommendation to use TNM staging for all SCLC cases.

The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer.

BACKGROUND: Small cell lung cancer (SCLC) is usually classified using the limited and extensive definition. The tumor, node, metastasis (TNM) classification should also be applicable to SCLC, but it has only been reported in small surgical series. The current analysis looks to the impact of the TNM system on the clinical staging of SCLC and of the new International Association for the study of Lung Cancer (IASLC) proposals. METHODS: Using the IASLC database, survival analyses were performed for clinically staged patients. Prognostic groups were compared, and the new IASLC TNM proposals were applied to this population and to the Surveillance, Epidemiology, and End Results (SEER) database. RESULTS: The IASLC database contained 12,620 eligible cases of small cell histology. TNM staging was available for 8088 patients. Survival was directly correlated to both T and N category. Differences were more pronounced in patients without mediastinal or supraclavicular nodal involvement. Stage grouping using the sixth edition of TNM also differentiates survival except between IA and IB. Patients with pleural effusion regardless of the cytology have an intermediate prognosis between limited and extensive disease. The IASLC proposals for the seventh edition of the TNM classification also apply to this series of SCLC and to the SEER database. CONCLUSION: TNM staging is recommended for SCLC, and stratification by stage I-III should be incorporated in clinical trials of early-stage disease. Further studies are needed to clarify the impact of pleural effusion and the extent of N3 disease.